Skip to Content

AI and patient safety

Senate House London
| Category: Latest feature

How can new treatments reach patients sooner without compromising safety? This was a central question at the DIA–MHRA Global Summit at London’s Senate House on 16-17 November, where regulators, researchers, pharmaceutical companies and patient groups discussed the future of medicines development.

Artificial intelligence (AI) was a recurring theme across the two-day event. Discussions explored how it could help researchers identify existing medicines that might be investigated as treatments for other conditions, including rare diseases with limited treatment options. However, identifying a promising medicine is only a starting point: research is still needed to establish whether it is safe and effective for a different use.

Earlier intervention was another priority, with speakers considering how healthcare could move beyond treating established illness towards identifying risk and acting sooner. They also highlighted a practical challenge: earlier detection must be matched by access to appropriate assessment, treatment and follow-up care.

Patient involvement ran throughout the discussions, particularly in designing clinical trials, improving participation and deciding how health data should be used. Speakers also considered the importance of including a wider range of patients in research so that new technologies do not carry forward existing gaps in evidence.

For people living with psoriasis and psoriatic arthritis, the discussions raise wider questions about how future research and regulation can respond to patients’ needs. The summit’s message was one of opportunity balanced with responsibility: closer collaboration and more adaptable regulation, while keeping patient safety at the heart of change.